Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines

MANILA, Philippines, March 25, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark), a leading research-led, global pharmaceuticals company has partnered with, Health Futures Foundation, Inc. (HFI) and the Municipality of Malinao to launch a comprehensive initiative to improve nutrition among children and pregnant/lactating women in the Philippines. This program, titled 'Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan,' aligns with the country's national health and development goals and will cover 23 Barangays. Its focus is to reduce the number of malnourished children aged 0-5 years and to support nutritionally-at-risk pregnant and lactating women. Additionally, the program will also empower community health workers to drive behavior change and advocate for improved health and nutrition outcomes, particularly for disadvantaged families.

This initiative marks Glenmark's first major social responsibility project in the Philippines. It underscores the company's commitment to global health solutions under its guiding core belief: 'Healthy Children are the Foundation of a Healthier World.' For this program, Glenmark and HFI are collaborating with local government offices, including the Municipal Health Office, Municipal Social Welfare Development and the Municipal Agriculture Office, to ensure seamless implementation. The long-term goal is to scale these efforts beyond Malinao to other underserved areas, impacting even more communities in need.

Speaking at the launch, Hon. Josephine I. Iquina, Municipal Mayor, Malinao said, "The fight against malnutrition requires a collective effort, and we appreciate Glenmark's commitment to improving nutrition and health outcomes in vulnerable communities. This initiative is a vital step in ensuring that mothers and children receive the nutrition they need while strengthening local capacity for long-term impact. By working with partners like Health Futures Foundation and the local government, Glenmark is playing a crucial role in advancing our national health agenda."

Tomas Mihal, Vice President and Regional Business Head - Asia Pacific, Glenmark Pharmaceuticals Ltd. said, "At Glenmark, we are proud to launch our first social responsibility project in the Philippines. The initiative aims to create sustainable solutions that address the root causes of malnutrition. By combining immediate support with long-term capacity building, we aim to empower local communities and health systems to break the cycle of malnutrition."

Adeel Hasan, Country Manager - Philippines, Glenmark Philippines Inc. said, "Addressing child malnutrition and maternal health is essential for Philippines' development. By partnering with local government and HFI, we ensure that our intervention is tailored to the community needs, creating lasting benefits for Filipino families."

Dr. Jaime Galvez Tan, Chairman of Health Futures Foundation, Inc., said, "This program is more than providing immediate aid; it is about empowering communities to take charge of their own health. Through nutrition gardening, training health workers, and fostering local leadership, we are laying the foundation for a healthier, more resilient future for the Philippines."

The project's structure is centered on three key interventions and aims to impact nearly 25,000 beneficiaries through:

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions.

For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

About Health Futures Foundation, Inc.

Health Futures Foundation, Inc. (HFI) is a non-stock, non-profit, non-government organization involved in the design and management of health and social development projects/programs in marginalized communities in the Philippines. HFI envisions "marginalized Filipino communities and vulnerable population groups achieve and sustain optimum health and development". Its mission is "to empower marginalized sectors and lend technical assistance to local governments in achieving access, quality, and equity in health and development through actual and virtual communities of wellness". Since 1998, HFI has implemented more than 85 projects all over the Philippines including community-based health and wellness programs, design and management of community training programs, health sector reviews, health policy analysis, health planning and programming, health emergency response, qualitative health research and assessment, and health governance.

For more information, visit www.healthfuturesfoundation.com or follow HFI on on LinkedIn (Health Futures Foundation, Inc.), Facebook (healthfutures), and Instagram (healthfutures).

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines

SINGAPORE, April 29, 2025 /PRNewswire/ -- Spanish fragrance house Eurofragance releases its financial results for 2024, showing unprecedented growth. With a 27% sales increase reaching €180 million like-for-like, the company continues to build on its strong upward trajectory year after year.

This performance underscores Eurofragance's strategic focus and commitment to excellence across all regions and product categories. Juan Ramón López Gil, the company's CFO, says: "Achieving €180 million in sales is a testament to our initiatives and the dedication of our teams. Each region's contribution has been instrumental in achieving these results and our financial discipline and focused strategies will continue to drive our success."

Widespread Expansion Across Categories and Regions

Eurofragance's results were driven by strong performances in key regions and product categories. All regions recorded significant growth in 2024, ranging from 19% in the EAT region (Europe, Africa, and Turkey) to 30% in IMEA, with APAC standing out with a strong performance at 23%. Joan Pere Jimenez, Chief Market Officer, adds: "We are capitalizing on the rapid development of dynamic markets such as Vietnam and Thailand. We are also benefiting from positive market trends in Indonesia where rising disposable income is fueling demand."

The multinational's diverse product portfolio also helped shore up significant gains. The Fine Fragrance category experienced a 28% upswing, while the Home and Personal Care segments saw a 20% increase. This cross-category progress highlights Eurofragance's ability to meet the demand of its customers in their expansion when it comes to offering them the right fragrances to grow their brands.

Expansion Fueled by Strategic Investments and Innovations

In 2024, Eurofragance continued to invest in strategic initiatives to support its growth. As part of this effort, the company is currently renovating its facilities in Singapore, including both the factory and the creative center, as well as renewing its premises in Jakarta, Indonesia. The fragrance house's expansion and optimism regarding the future are also evident in its commitment to talent. With new hires across all affiliates and substantial investment in its professional development academies and its talent management program, Eurofragance's workforce grew by 15% in 2024.

The Spanish fragrance house also launched Euphorionâ„¢, its first synthetic addition to its ICON Captives collection, a perfumery ingredient that offers a new take on freshness in the perfumer's palette. Laurent Mercier, who has been at the helm of Eurofragance as CEO for the past seven years has played a key role in the accelerated development of the company and its foray into the design of proprietary fragrance ingredients. Mercier explains: "Our disciplined approach to growth and strategic investments in key areas have allowed us to maintain our reputation as a leading player in the fragrance industry. The strategies we have in place will ensure our sustained expansion, and our commitment to innovation will continue to drive our success in the years to come."

Relentless Commitment to People and Planet

Eurofragance remained steadfast in its commitment to sustainability, earning the highest possible rating from EcoVadis with a Platinum medal. The company's dedication to community engagement was and continues to be evident through its participation in programs such as "Empowering Women's Talent" and "Diversity Leading Company" both organized by the top-tier Human Resources media outlet in Spain Equipos&Talento. Additionally, Eurofragance collaborated with Hospital Sant Joan de Déu Barcelona and MartiDerm dermocosmetics company on a solution for fish odor syndrome, which received a silver medal award at the VPC Green Beauty Awards.

Eurofragance's performance in 2024 reflects its strategic vision, innovative spirit and commitment to its people, sustainability and community. As the company looks to the future, it remains dedicated to driving growth and delivering value to its customers and stakeholders.

About Eurofragance

Eurofragance manufactures and markets the highest quality fragrances for worldwide brands in fine perfumery, home, personal and air care. The company is a privately held B2B enterprise founded on family values in Barcelona in 1990 and currently has over 550 employees.

Driven by a passion for perfume and the entrepreneurial spirit of its founders, Eurofragance first grew in Europe and the Middle East, before taking on the Far East and the Americas. The company is now represented on five continents; runs its own plants in Spain, Singapore and Mexico; and works with manufacturing partners in China and India.

Eurofragance's international network of Creative Centers and outstanding manufacturing capabilities enable it to create and deliver fragrances around the world. Over the years, Eurofragance has cultivated lasting relationships and has grown hand in hand with its partners.

Eurofragance is wholeheartedly invested in addressing sustainability issues and its decision-making process is built around strategic initiatives supporting this cause. The company spearheads activities around four major axes: safety, community, business ethics and resources.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Eurofragance Strengthens Market Position with €180M in Sales for 2024